The FDA recently approved use of the drug, Journavx, as a pain killer alternative to opioids. The first new pain killer approved in 25 years by the agency, it gives patients an opioid-free option reducing the risk of addiction.
Is it as effective as traditional painkillers? How does it work differently in the body? What effect, is any, will it have on the growing opioid epidemic in the United States?
Drs. Jacqueline Cleary and Amanda Engle, pharmacists from Albany College of Pharmacy and Health Sciences, are available to offer insight on this new drug approval. As pharmacists embedded in the community, they know the drug well and understand its ramifications.
Both pharmacists are also intimately involved in ACPHS’ commitment to raising awareness and training to combat the opioid crisis, especially in the Capital Region. They host trainings in the community and are part of coalition focused on opioid use disorder prevention, treatment or recovery, as well as supportive services such as housing and transportation, supported by the $2M Albany County’s Opioid Settlement Fund.
ACPHS experts include:
- Jacqueline H. Cleary, Pharm.D., BCACP
PGY2 Ambulatory Care Pharmacy Residency Program Director
Associate Professor of Pharmacy Practice
- Amanda Engle, PharmD, BCPS
Assistant Professor
Director, Interprofessional Education
Drs. Cleary and Engle are available for in-studio or Zoom interviews.